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Cancer/testis (CT) antigens are a recently recognized category of
tumour antigens that are expressed in a variety of malignant
neoplasms, but silent in normal tissues except testis. For this
reason, CT antigens appear to be ideal targets for immunotherapy
of human cancer (Boon and Old, 1997; Van den Eynde and Boon,
1997). There are now ten genes or gene families coding for anti-
gens with these characteristics (De Plaen et al, 1994; Lurquin et al,
1997; Sahin et al, 1997; Chen and Old, 1998; Lucas et al, 1998).
MAGE genes, the first family of genes coding for CT antigens to
be recognized, code for tumour products with a characteristic
pattern of CT expression, and MAGE-1 was the first MAGE gene
identified (Van der Bruggen et al, 1991; Traversari et al, 1992).
Current knowledge of CT antigen expression is mainly based on
the analysis of mRNA, and little is known about actual protein
expression of these antigens. We previously generated a mono-
clonal antibody, designated MA454, to MAGE-1 recombinant
protein (Chen et al, 1994). Although MA454 identified the MAGE
gene product in western blots and ELISA, it could not detect the
antigen in tissue specimens using techniques available. Recent
advances in antigen retrieval techniques have prompted us to
reanalyse the immunohistochemical reactivity of MA454.
In previous studies, MAGE-1 mRNA was found to be expressed
in a high percentage of pulmonary neoplasms (Van den Eynde and
Van der Bruggen, 1997). The present study assesses the reactivity
of mAb MA454 with normal tissues and with a series of lung
neoplasms. Furthermore, we compared MA454 reactivity with
expression of MAGE-1 mRNA by RT–PCR.
MATERIALS AND METHODS
Tissues
Tissues were obtained from the Departments of Pathology of
Memorial Sloan-Kettering Cancer Center and New York
Hospital/Cornell University Medical School. The specimens
consisted of O.C.T.-mounted (Tissue Tek, Torrance, CA), snap-
frozen tissue samples and formalin-fixed, paraffin-embedded
tissue blocks. Five mm sections were cut from frozen and paraffin
blocks and were applied to histology slides for immunohistochem-
istry (Superfrost Plus, Fisher Scientific, Pittsburgh, PA). A panel
of normal tissues and a series of lung neoplasms were tested as
indicated in Table 1 and Table 2. The lung tumours were also
analyzed by RT–PCR for the presence of MAGE-1 mRNA.
Immunohistochemistry
The generation of MA454, a murine IgG1 mAb to the MAGE-1
recombinant protein, was previously described (Chen et al, 1994).
Initial titration and reactivity assessments were done on frozen and
paraffin testicular specimens. Testis was also used as a positive
control tissue in subsequent assays. For frozen tissues, different
fixation protocols such as acetone and formaldehyde solutions
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were tested. Staining of paraffin sections was tested without any
pretreatment, as well as with heat-based antigen retrieval methods
using citrate buffer (10 mM, pH 6.0), EDTA buffer (1 mM, pH 8.0)
and commercial retrieval solutions like DAKO-TRS (DAKO,
Carpintera, CA), and DAKO hipH. The primary antibody was
detected with a biotinylated horse anti-mouse-secondary reagent
(1:200; Vector Laboratories, Burlingham, CA) followed by an
avidin-biotin-complex system (Vector) using diaminobenzidine
tetrahydrochloride (DAB, Biogenex, San Ramon, CA) as a chro-
mogen. The extent of immunohistochemical reactivity in tumour
tissues was estimated by light microscopy and graded according to
the number of immunoreactive cells in 25% increments: ‘focal’
indicating staining of single cells or small clusters of cells (not
more than 5% cells stained); + = <25%, ++ = 25–50%, +++ =
50–75%, and ++++ = >75% of cells stained. A weak staining
intensity was indicated by ‘w’. Control slides consisted of testis
tissue as a positive control; negative control slides were incubated
with buffer instead of MA454.
RT–PCR
In order to determine the specificity of MA454, lung tumours were
typed for MAGE-1 by RT–PCR and the results were compared
with MA454 immunohistochemical staining. RT–PCR was done
as previously described (Chen et al, 1994). Briefly, total RNA was
extracted from 20 mm sections of corresponding frozen tissue
blocks. Testicular tissue was used as a positive control tissue. RNA
was reverse transcribed into cDNA and PCR-amplified with
AmpliTaqGold (Perkin Elmer, Norwalk, CT) for 30 cycles in a
Table 1 Immunohistochemistry of MA454 in formalin-fixed paraffin-
embedded normal tissues
Tissue MA454
Oesophagus –
Stomach –
Duodenum –
Small intestine –
Colon –
Appendix –
Liver –
Pancreas –
Parotid gland –
Kidney –
Ureter (renal pelvis) –
Urinary bladder –
Prostate –
Testis positive
Uterus (cervix/endometrium) –
Fallopian tube –
Ovary –
Breast –
Placenta –
Skeletal muscle –
Thyroid gland –
Adrenal gland –
Lymph node –
Thymus –
Spleen –
Tonsil –
Heart –
Lung –
Skin –
Peripheral nerve –
Table 2 Immunoreactivity of MA454 with formalin-fixed paraffin-embedded
lung tumours
Case Diagnosis MAGE-1 MA45
4-immunoreactivitya
mRNA
1 LCC – –
2 ADC +b +
3 LCC +b foc.
4 SQCC – foc. w
5 ADC +b foc.
6 ADC +b +
7 SQCC – –
8 ADC – –
9 ADC – –
10 ADC – foc.
11 ADC – –
12 LCC + foc.
13 ADC – –
14 ADC + –
15 ADC + foc.
16 SQCC + –
17 ADC + + w
18 LCC – –
19 ADC – –
20 ADC, BA – –
21 carcinosarcoma +b +
22 ADC – –
23 ADC, papillary – –
24 SQCC +b + w
25 ADC with focal SQCC – –
differentiation
26 LCC – foc.
27 SQCC – –
28 ADC, BA – –
29 ADC + ++++
30 ADC – –
31 ADC – –
32 SQCC – –
33 SQCC n.a. ++
34 ADC, BA n.a. –
35 ADC – –
36 ADC – –
37 SQCC + ++
38 SQCC n.a. –
39 ADC – –
40 SQCC + foc.
41 ADC + +
42 ADC, BA – –
43 ADC + ++
44 ADC – –
45 LCC – –
46 LCC – –
47 ADC n.a. –
48 ADC – –
49 ADC – –
50 SQCC – –
51 ADC – –
52 LCC + +
53 SQCC – –
54 ADC – –
55 LCC – –
56 ADC – –
57 ADC, clear cell – –
58 ADC n.a. –
59 ADC, papillary – –
agrading of immunohistochemical tumour staining as follows: foc.:
immunoreactivity approximately <5%, +: 5–25%, ++: 25–50%, +++:5 0–75%,
++++: >75%, ‘w’ weak immunostaining, bsequence analysis of RT-PCR
product, n.a.: not available, LCC: large cell undifferentiated carcinoma,
SQCC: squamous cell carcinoma, ADC: adenocarcinoma, ADC, BA:
adenocarcinoma, bronchioalveolar type.thermal cycler (Perkin Elmer) at an annealing temperature of
60°C. Oligonucleotide primers CHO-12 and CHO-14 were used to
detect MAGE-1 (Brasseur et al, 1992); both primers were synthe-
sized commercially (GIBCO, Grand Islands, NY). RT–PCR prod-
ucts were visualized with ethidium bromide. In order to confirm
the specificity of the RT–PCR products, a sequence analysis was
performed commercially (Bioresource Center, Cornell University,
Ithaca, NY) for 6 representative tissues (cases #2, #3, #5, #6, #21,
#24).
RESULTS
MA454 showed poor reactivity in frozen tissue sections.
Reproducible, strong immunoreactivity was observed in formalin-
fixed, paraffin-embedded standard archival tissue when using an
antigen retrieval technique. Hence, further assays were done on
formalin-fixed paraffin-embedded tissues. The best staining was
achieved after heating sections at 90°C in EDTA for 30 minutes. A
biotin/avidin blocking kit (Vector, Elite) was used to suppress the
background staining due to endogenous biotin activity.
Table 1 summarizes the immunohistochemical staining proper-
ties of MA454 in normal tissues. No staining could be observed in
any normal tissue except testis. The testicular immunoreactivity
was confined to components within the seminiferous tubules and
staining was restricted to germ cells. Spermatogonia showed
strong immunoreactivity, with a lesser degree of staining in
primary spermatocytes. A consistent strong cytoplasmic staining
of spermatogonia was observed. Germ cells at later maturation
stages, e.g. spermatocytes, showed a more variable labelling of the
cytoplasm. This staining varied from none to mostly faint and
occasionally moderate in spermatocytes, depending on the concen-
tration of MA454 and the particular specimen used. As with sper-
matogonia, staining of spermatocytes was cytoplasmic with no
significant nuclear reactivity. Spermatids, Sertoli cells, and inter-
tubular tissue components such as Leydig cells remained
immunonegative (Figure 1A, B).
Table 2 summarizes the results of immunohistochemical
staining and RT–PCR analysis of the lung tumours. Fifty-nine
cases were available for immunohistochemical evaluation. All
except one case of carcinosarcoma were non-small cell lung carci-
nomas. From 54 cases, fresh tissue for RT–PCR analysis was also
available. Immunohistochemistry revealed immunopositivity with
MA454 in 19/59 cases (32%). However, in the vast majority of
tumours, MA454 revealed a predominantly heterogeneous reac-
tivity pattern (Fig. 1C–F), with ‘focal’ immunoreactivity (8 cases)
or immunoreactivity in <25% of the tumour (7 cases). These
tissues showed MA454 positive single tumour cells or small
tumour nests (Fig. 1C, F). Only in 4 tissues was staining seen in
wider areas (>25%) of the tumour. One of these 4 cases (Fig. 1D)
revealed homogenous immunoreactivity in all neoplastic areas
(‘++++’). The cellular staining pattern was cytoplasmic and no
nuclear staining was observed (Fig. 1E). Among 37 adenocarci-
noma cases in our series, 9 were immunoreactive. Of the 12 squa-
mous cell carcinoma and 9 large cell undifferentiated carcinoma
cases, 5 and 4 cases were MA454 positive, respectively. The carci-
nosarcoma was also MA454 positive. The 4 cases with more wide-
spread MA454-reactivity were two squamous cell carcinomas and
two adenocarcinomas. In case 43, two blocks were available for
analysis: while one block showed staining in more than 25% of the
tumour, the other block revealed a focal staining. RT–PCR showed
the presence of MAGE-1 mRNA in 17/54 cases (32%). The
sequencing analysis of the RT–PCR products confirmed the pres-
ence of MAGE-1 mRNA. The results of RT–PCR typing matched
IHC staining in 49 of the 54 cases (91%). Of the 5 cases that did
not co-type with MA454 expression, 3 were MAGE-1 mRNA
negative and IHC positive, whereas two cases were mRNA posi-
tive and MA454 negative. All MA454 positive and MAGE-1
RT–PCR negative cases showed focal immunoreactivity.
DISCUSSION
A number of serological reagents for the evaluation of MAGE
protein expression has been generated (Chen et al, 1994; Schultz-
Thater et al, 1994; Kocher et al, 1995; Takahashi et al, 1995;
Carrel et al, 1996; Jurk et al, 1998). One of the most intensely
studied MAGE reagents is 57B, a mAb generated against MAGE-
3 recombinant protein (Fischer et al, 1997; Hofbauer et al, 1997;
Cheville and Roche, 1999). Although initially thought to have
specificity for MAGE-3, subsequent analysis with COS cells
transfected with individual MAGE genes, has shown that 57B
detects MAGE-1, -2, -3, -4, -6, and -12 (M Godelaine, personal
communication). With regard to MAGE-1, several monoclonal
antibodies have developed. Mab 6C1 reacts with MAGE-10 as
well as MAGE-1 (Carrel et al, 1996; Rimoldi et al, 1999), and the
fine specificity of 77B has not been reported (Gudat et al, 1996;
Zuber et al, 1997). MA454, the anti-MAGE-1 mAb used in this
analysis, originally did not show cross-reactivity with other
MAGE proteins (Chen et al, 1994). Carrel et al (1996) describing
the generation of their anti-MAGE mAb 6C1 included MA454 and
did not find any indication of MA454 cross-reacting with other
proteins but MAGE-1. Recently, an immunohistochemical
analysis of a panel of MAGE-transfected cells, also confirmed that
MA454 was specific for MAGE-1 and did not react with MAGE-
2, -3, -4, -6, -8, and -9 to -12 (M. Godelaine, manuscript in prepa-
ration).
In the initial analysis of MA454, no immunoreactivity could be
shown using frozen tumour specimens (Chen et al, 1994).
However, when antigen retrieval techniques are used, MA454
shows strong reactivity on formalin-fixed paraffin-embedded
specimens. Antigen retrieval has only recently become an impor-
tant tool for immunohistochemistry and is now employed as a
standard procedure in pathology (Shi et al, 1996). At this point, we
can only speculate about reasons for recovering MAGE-1 reac-
tivity after antigen retrieval. Possibly the structure of the denatured
MAGE-1 recombinant protein used for immunization resembles
the antigen present in formalin-fixed, paraffin-embedded tissues
after antigen retrieval more closely than its acetone-fixed counter-
part. Another possibility is that antigen retrieval exposes epitopes
not accessible in acetone-fixed specimens.
In the present study, the immunoreactivity of MA454 with
normal tissues closely correlated with the known MAGE-1 mRNA
expression pattern (De Plaen et al, 1994) i.e. only testis was
immunoreactive. With regard to spermatogenic cells, MA454
staining contrasts with the pattern seen with mAb 57B, anti-
MAGE-4 mAb R5 and a MAGE-1 polyclonal reagent (Takahashi
et al, 1995; Itoh et al, 1996; Jungbluth et al, 2000). The latter three
mAbs give a strong nuclear staining, while MA454 is confined to
the cytoplasm. The staining of later stage germ cells, i.e. spermato-
cytes, varied, ranging from mostly faint and moderate to no
staining, depending on MA454 concentrations and individual
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specimens. Thus, MAGE-1 protein is present in early stages of
germ cell maturation, with the highest level of expression in sper-
matogonia and decreasing expression levels inversely paralleling
germ cell maturation. As little is known about the biological func-
tion of the MAGE-proteins, an interpretation of these different
staining patterns is difficult. The expression pattern of different
MAGE proteins suggests that each gene plays a different role in
different stages of germ cell maturation.
In this series of lung neoplasms, frozen and paraffin tissues were
available for most cases and side by side immunohistochemistry
and RT–PCR typing could be performed. Previous mRNA
analyses for MAGE-1 expression of lung tumours have varied
widely: 11% (Sakata, 1996), 20% (Ferlazzo et al, 1996), 35%
(Weynants et al, 1994), 49% (Van Den Eynde and Van der
Bruggen, 1997) or more than 60% (Fischer et al, 1997). In our
series, 32% of the tumours expressed MAGE-1 by RT–PCR, and
immunohistochemical staining with MA454 revealed 32%
positive tumours. Overall, protein expression correlated well 
with the mRNA analysis, most of the RT–PCR-positive tissues
showing some degree of MA454 immunoreactivity. Similar to
AB
1000mm 50mm
500mm
D
1000mm
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50mm 100mm
Figure 1 Immunohistochemical staining with MA454, normal testis (A, B) and lung carcinomas (C–F). Avidin-biotin technique, chromogen DAB, haematoxylin
counterstain. (A) Normal testis. Staining of germ cells within seminiferous tubules. Negative interstitial tissue. (B) Seminiferous tubule. Intensely stained
spermatogonia and variable staining of spermatocytes. Spermatids and Sertoli cells not stained. (C) Squamous cell carcinoma (case 33). An area of MA454
reactivity next to an immunonegative tumour area. (D) Adenocarcinoma (case 29). Homogeneous immunoreactivity in all tumour areas. (E) Squamous cell
carcinoma (case 37). Intense cytoplasmic staining, negative nuclei. (F) Adenocarcinoma (case 41). Heterogeneous staining pattern, intensely immunopositive
cells next to negative cellsMAGE-1 antigen expression (mAb MA454) in lung tumours 497
British Journal of Cancer (2000) 83(4), 493–497 © 2000 Cancer Research Campaign
spermatogenic cells, staining was restricted to cytoplasm of the
tumour cells and no significant nuclear immunoreactivity was
observed. Cytoplasmic localization of the MAGE-1 antigen was
previously shown by cell fractionation studies of cultured tumour
cells using mAb MA454 (Amar-Costesec et al, 1994) and by
immunofluorescence in cultured cells with mAb 77B (Schultz-
Thater et al, 1994; Gudat et al, 1996).
In our immunohistochemical analysis, 4 cases showed expres-
sion in >25% of the tumour; only 1 of these gave homogeneous
staining. However, most tumours showed a restricted ‘focal’
staining or immunoreactivity in less than 25% of the tumour. This
extreme heterogeneous immunoreactivity likely explains the
discrepancy between mRNA- and MA454 expression in 5 cases as
due to error variations. This is supported by the fact that all
discrepant MA454-positive/RT–PCR negative cases revealed only
focal immunoreactivity. Due to the predominance of immunoneg-
ative areas, samples could easily contain solely non-reactive cells.
Also, degradation of mRNA in tissue specimens cannot be
excluded. The heterogeneity with MA454 is more pronounced
than we saw in our previous study with mAb 57B (Jungbluth et al,
2000). This is probably due to the fact that 57B is essentially a
polyvalent MAGE reagent. Tumour 43, a case in which 2 paraffin
blocks were available for assessment, illustrates the heterogeneous
expression of MAGE-1 even in a single patient. While one block
showed focal reactivity, the other block revealed immunostaining
in almost 50% of the tumour. A similar heterogeneity was
observed in a limited number of melanoma specimens with mAb
77B (Zuber et al, 1997). Genomic demethylation has been associ-
ated with the activation of the MAGE-1 gene (De Smet et al,
1996), but how this relates to expression by some tumours and not
by others is unexplained. As homogeneously expressed antigens
are preferred targets for immunotherapy, MAGE-1 might not be a
sufficient sole target for immunotherapeutic approaches in lung
neoplasms. Though mRNA expression analyses might suggest a
high percentage of positive tumours for any particular antigen, our
investigation demonstrates that an immunohistochemical exami-
nation renders a different picture for protein expression and is
essential for the evaluation of targets for immunotherapy.
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